Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 15romidepsin 9Whole-Body Irradiation 9fludarabine phosphate 8Vincristine 8Etoposide 8Doxorubicin 8Prednisone 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 7Brentuximab Vedotin 610-propargyl-10-deazaaminopterin 6Rituximab 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Cyclosporine 5denileukin diftitox 4Nivolumab 4Lenalidomide 4mogamulizumab 3Tacrolimus 3Methotrexate 3Immunohistochemistry 3Gene Expression Profiling 3Dexamethasone 3Alemtuzumab 3selinexor 2pembrolizumab 2pegfilgrastim 2liposomal doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell, Peripheral × HBI-8000 × Clear all
NCT02953652 2024-09-19

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

HUYABIO International, LLC.

Phase 2 Completed
55 enrolled 18 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡